[{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pfenex \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ Serum Institute of India Private Limited"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pharmaceuticals \/ Palvella Therapeutics"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Vernalis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ Not Applicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pfenex","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.52000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Taurus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Xcella Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Hovione","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Modified Cyclodextrin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Ligand"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pfenex","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.52000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ Ligand"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Asparaginase Erwinia Chrysanthemi (recombinant)-rywn","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Merck"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Gloria Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Zimberelimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ligand Pharmaceuticals \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Ligand"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CR Double-Crane Pharmaceuticals Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"BEPro-enabled COVID-19 antiviral","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ Double-Crane Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ligand Pharmaceuticals \/ Double-Crane Pharmaceutical"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Sermonix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"OmniAb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Demerger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Novan","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Novan"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Berdazimer Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Berdazimer Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Soticlestat","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Teplizumab-mzwv","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Sirolimus","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ligand Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ligand Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Invios","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"INV501","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ligand Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals by Ligand Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
